Episode Summary
Executive Summary: Ben Lamm, CEO of Colossal Biosciences, discusses building the world’s first de-extinction and species-preservation company, including dire wolf births, woolly mouse experiments, and plans for mammoths, dodos, thylacines, and moas. He frames de-extinction as a venture-scale platform for conservation, biotech spin-outs, government partnerships, and future human-health applications, while addressing ethics, dual-use risk, and public skepticism.
Main Topics: Colossal’s de-extinction mission and flagship species (Priority: 5/5): Lamm explains Colossal’s goal of rebuilding extinct species and preserving existing ones through biobanking, genetic engineering, and rewilding plans, highlighting mammoth, thylacine, dodo, moa, and dire wolf work. Dire wolf project as proof of platform capability (Priority: 5/5): He details how Colossal used ancient DNA, computational biology, and multiplex editing to create dire wolf pups, arguing this is the first successful de-extinction because extinct genes were engineered into a living species. Business model: R&D platform, spin-outs, licensing, and governments (Priority: 5/5): Colossal is not only a science project; it is building a venture-scale platform that spins out companies, licenses IP, and sells conservation and genetics capabilities to governments and partners. Conservation and climate rationale (Priority: 4/5): Lamm argues de-extinction and species preservation should complement traditional conservation, especially by restoring keystone species that can reshape ecosystems and improve biodiversity and carbon sequestration. Dual-use, ethics, and public reaction (Priority: 4/5): The conversation addresses concern that powerful synthetic biology could be misused, along with debates over whether de-extinction is ethical or justifiable versus spending on existing conservation efforts. Technology spillovers into human health and industry (Priority: 4/5): He describes how tools developed at Colossal are already yielding adjacent businesses and applications in drug discovery, plastic degradation, IVF, and potentially other human-health uses. Leadership, transparency, and public education (Priority: 3/5): Lamm emphasizes that polarizing science needs openness, explanation, and media engagement to reduce fear, inspire future scientists, and build legitimacy around controversial breakthrough technologies.
Key Arguments: Colossal’s work is framed as a platform, not a one-off stunt: ancient DNA, AI, robotics, and synthetic biology can be turned into repeatable systems for conservation and commercialization. The dire wolf project is presented as the first true de-extinction because extinct DNA was mapped to a living relative and edited into puppies within 18 months. Traditional conservation remains essential, but it is too slow and underfunded to match current biodiversity loss; de-extinction and preservation tools can act as a “safety net.” Restoring keystone species can have ecosystem-wide benefits, as illustrated by wolf reintroduction in Yellowstone and the expected role of mammoths in Arctic ecology. Colossal’s business model includes spin-outs, IP licensing, government contracts, education products, and a nonprofit foundation, making the company viable beyond headline science. Technologies developed for de-extinction can spill over into major markets, including drug discovery, plastic degradation, and reproductive medicine. Synthetic biology is powerful and potentially dual-use, so the U.S. should lead, regulate thoughtfully, and keep the public informed rather than pretend the technology can be stopped. Public fascination matters: flagship species like mammoths and dire wolves can inspire children and future scientists while creating broader support for conservation. Data Points: Capital raised: over $400 million - Funding raised by Colossal Biosciences Valuation: north of $10 billion - Implied company valuation during the interview Dire wolf pups born: 3 - Romulus, Remus, and Khaleesi Time since dire wolves existed: 12,000 years - Colossal says it birthed the first dire wolves in 12,000 years Dire wolf project timeline: 18 months - From ancient skull/tooth samples to puppies Woolly mice created: about 36 - South by Southwest demonstration project Positive media reaction to dire wolves: 68% positive - Lamm says media response was unexpectedly favorable Negative media reaction to dire wolves: 5% negative - He contrasts this with expected backlash Media coverage: 25,000+ stories - Coverage generated by the dire wolf announcement Genome editing scale: 95+ edits at a time - Colossal’s multiplex editing capability DNA synthesis scale: 3x more than anything published - Claim about size of synthesized DNA pieces inserted Conservation foundation funding: $50 million - Capital raised for the Colossal Foundation Universities supported: 17 - Colossal Foundation funding partnerships Conservation partners supported: 60 - Colossal Foundation ecosystem Government partners: 3 governments - Working closely with governments on existing species and conservation Animal care staff for dire wolves: 10 full-time care people - Dire wolf welfare and management team Secure preserve size: 2,000 acres - Where the dire wolves are housed EEHV elephant mortality: about 20% of elephants every year - Disease target for Colossal’s elephant vaccine work Conservation funding gap: hundreds of billions annually - Lamm’s estimate of shortfall versus what is needed Biodiversity loss forecast: up to 50% in 25 years - Species loss risk cited in the conversation Thylacine gestation: 13.5 days - Example of differing cloning/reproduction challenges across species Mammoth gestation: 22 months - Illustrates difficulty of mammoth reproduction
Pivotal Quotes: "This is the first time that ancient DNA, we've mapped ancient DNA to their closest living relative and engineered those lost genes into that of a living species." — Ben Lamm: Defending the claim that Colossal achieved the first successful de-extinction with dire wolves "We are that 0.0001% of like, we're just a safety debt." — Ben Lamm: Explaining Colossal’s view that it complements rather than replaces traditional conservation "Synthetic biology, powered by AI and quantum, is significantly more powerful than nuclear weapons or anything else that we could ever think of." — Ben Lamm: Discussing dual-use risk and why the U.S. must lead in this field
Implications: The interview suggests de-extinction is becoming a real venture category, not just speculative science. Expect more convergence of AI, genomics, conservation, and biotech commercialization, alongside stronger debate over ethics, governance, and biosecurity.